Genetic Technologies Ltd. (Nasdaq: GENE) announced that up to six new breast
diagnostic/treatment centers would begin offering its BREVAGenplus
predictive risk test. The stock price more than tripled by leaping $2.99 to $4.27.
More centers to offer Genetic Technologies' BREVAGenplus
January 29, 2015 at 14:03 PM EST
